Pancreatic Cancer
Phase III clinical data from Tarceva trial presented
Published in Obesity and Diabetes Week, June 27th, 2005
Tarceva is the first drug to significantly improve survival in a phase III trial when added to gemcitabine chemotherapy in first-line pancreatic cancer compared to gemcitabine alone. These data were presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO).
"These ongoing trials reinforce our belief in the potential application of Tarceva in a variety of cancers," said Gabe Leung, president of (OSI) Oncology at OSI Pharmaceuticals. "Based on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes
Adiponectin is promising therapeutic target for metabolic and vascular disease - Diabetes Therapy
AMP-activated protein kinase may prevent insulin resistance - Obesity Pathogenesis
Adipocyte adhesion molecule critical to development of obesity - Obesity Pathogenesis
PGC-1 beta variation linked to obesity - Stroke Risk Factors
Body fat distribution may predict long-term risk of stroke mortality - Addiction Medicine
Lipid oxidative stress evaluated in bariatric candidates with NAFLD - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
